Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Core Viewpoint - Eyenovia, Inc. is seeking stockholder approval for a reverse stock split to comply with Nasdaq's Minimum Bid Price Requirement, with recommendations from leading proxy advisory firms ISS and Glass Lewis to vote "FOR" the proposal [1][2]. Meeting Details - The 2025 Special Meeting of Stockholders is scheduled for January 21, 2025, at 10:00 a.m. ET, and stockholders must pre-register by January 20, 2025, at 11:59 p.m. ET [3]. - Stockholders of record as of December 9, 2024, are eligible to vote [3]. Proposed Items for Vote - The reverse stock split will be considered among four proposed items at the Special Meeting, including: 1. Approval of a reverse stock split at a ratio of between 1:40 and 1:80 [7]. 2. Amendment to the 2018 Omnibus Stock Incentive Plan to reserve an additional 350,000 shares [7]. 3. Approval for potential issuance of up to 73,029,273 shares upon the exercise of certain outstanding warrants [7]. 4. Authorization for adjournment of the Special Meeting if necessary [7]. Company Overview - Eyenovia, Inc. is an ophthalmic technology company developing the Optejet platform for topical ophthalmic medication, aimed at improving treatment compliance for ocular lubrication and chronic front-of-the-eye diseases [5].